Skip to main content
European Medicines Agency's logo Go to homepage
English
Select your language
българскиespañolčeštinadanskDeutscheestiελληνικάEnglishfrançaisGaeilgehrvatskiitalianolatviešu
lietuviųmagyarMaltiNederlandspolskiportuguêsromânăslovenčinaslovenščinasuomisvenskaÍslenskanorsk
Select how you want to search using keywords
  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Podcast: Inside EMA
    • Campaigns
    • Speeches
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Academia
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
    • One Health approach
    • Animal health professionals
    • One substance - one assessment
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Welireg - opinion on variation to marketing authorisation

Welireg - opinion on variation to marketing authorisation

Opinion

EMA has issued an opinion on a change to this medicine's authorisation

belzutifan
Post-authorisationHuman

Page contents

  • Opinion
  • Key facts
  • News on Welireg
  • More information on Welireg

Opinion

On 12 November 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Welireg. The marketing authorisation holder for this medicinal product is Merck Sharp & Dohme B.V. 

The CHMP adopted a new indication, as follows: 

Welireg, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced clear cell renal cell carcinoma that progressed following prior therapy that included a PD‑(L)1 inhibitor.

For information, the full indications for Welireg will be as follows:

Renal cell carcinoma (RCC)

Welireg, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced clear cell renal cell carcinoma that progressed following prior therapy that included a PD‑(L)1 inhibitor. 

Welireg is indicated as monotherapy for the treatment of adult patients with advanced clear cell renal cell carcinoma that progressed following two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies.

von Hippel-Lindau (VHL) disease-associated tumours

Welireg is indicated as monotherapy for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable. 

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission. 


Note: New text in bold

CHMP post-authorisation summary of positive opinion for Welireg (VR-0000326853)

Adopted Reference Number: EMADOC-1700519818-3555535

English (EN) (119.46 KB - PDF)

First published: 13/11/2026
View

Key facts

Name of medicine
Welireg
EMA product number
EMEA/H/C/005636
Active substance
belzutifan
International non-proprietary name (INN) or common name
belzutifan
Therapeutic area (MeSH)
  • Carcinoma, Renal Cell
  • von Hippel-Lindau Disease
Anatomical therapeutical chemical (ATC) code
L01XX74

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see Conditional marketing authorisation.

Marketing authorisation holder
Merck Sharp & Dohme B.V.
Date of opinion
12/11/2026
Status
Positive

News on Welireg

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026
13/11/2026
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2024
13/12/2024
First medicine to treat rare genetic disorder causing cysts and tumours
13/12/2024

More information on Welireg

  • Welireg
This page was last updated on 13/11/2026

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
About this website
Languages
Accessibility
Glossaries
Cookies
Website data protection notice
Data protection at EMA
Frequently asked questions
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • BlueskyFollow EMA on Bluesky. Opens in a new window.
  • YouTubeFollow EMA on YouTube. Opens in a new window.
  • LinkedInFollow EMA on LinkedIn. Opens in a new window.
© 1995 - 2026 European Medicines Agency
European Union agencies network
An agency of the European Union